U.S. markets close in 4 hours 33 minutes

Xenetic Biosciences, Inc. (XBIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.8298-0.0846 (-9.25%)
As of 11:22AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.9144
Open0.8900
Bid0.8300 x 1300
Ask0.8306 x 900
Day's Range0.8200 - 0.8917
52 Week Range0.4400 - 1.8500
Volume162,110
Avg. Volume287,195
Market Cap5.225M
Beta (5Y Monthly)2.41
PE Ratio (TTM)N/A
EPS (TTM)-2.4470
Earnings DateAug 13, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ACCESSWIRE

    Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

    Live video webcast with CEO, Jeffrey Eisenberg, on Wednesday, September 16th at 12:00 PM EDTFRAMINGHAM, MA / ACCESSWIRE / September 9, 2020 / Xenetic Biosciences, Inc.

  • Benzinga

    Overview Of Value Stocks In The Healthcare Sector

    Understanding Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued.Below is a list of notable value stocks in the healthcare sector: 1. Cronos Group (NASDAQ: CRON) - P/E: 2.57 2. Viveve Medical (NASDAQ: VIVE) - P/E: 0.08 3. Brookdale Senior Living (NYSE: BKD) - P/E: 6.3 4. Five Star Senior Living (NASDAQ: FVE) - P/E: 3.92 5. Xenetic Biosciences (NASDAQ: XBIO) - P/E: 0.74Cronos Group saw a decrease in earnings per share from 0.2 in Q1 to -0.19 now. Cronos Group does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.This quarter, Viveve Medical experienced an increase in earnings per share, which was -0.82 in Q1 and is now -0.45. Viveve Medical does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Brookdale Senior Living has reported Q2 earnings per share at -0.65, which has decreased by 822.22% compared to Q1, which was 0.09. Brookdale Senior Living does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Five Star Senior Living reported earnings per share at 0.1, whereas in Q1 earnings per share sat at -0.55. Five Star Senior Living does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Xenetic Biosciences reported earnings per share at -0.15, whereas in Q1 earnings per share sat at -0.19. Xenetic Biosciences does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.See more from Benzinga * 5 Value Stocks To Watch In The Real Estate Sector * A Look Into Catalent's Debt * Fastenal: Debt Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • ACCESSWIRE

    Xenetic Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Corporate Update

    \\- Successfully established two strategic academic collaborations in Q2 2020 to advance development of XCART™, its differentiated CAR T therapy platform - \\- Strengthened panel of experts on the Scientific Advisory Board, bringing valuable expertise across all phases of preclinical and clinical development -FRAMINGHAM, MA / ACCESSWIRE / August 13, 2020 / Xenetic Biosciences, Inc.